This announcement is a separate document:
信達生物：自願公告 - 國家藥品監督管理局批准耐立克（奧雷巴替尼片）用於治療對一代和二代TKI耐藥和/或不耐受的CML-CP患者
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES OLVEREMBATINIB FOR THE TREATMENT OF CML-CP PATIENTS WHO ARE RESISTANT AND/OR INTOLERANT TO 1st AND 2nd GENERATION TKI TREATMENT
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.